305 related articles for article (PubMed ID: 33457427)
1. Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients.
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
J Immunol Res; 2020; 2020():5618786. PubMed ID: 33457427
[TBL] [Abstract][Full Text] [Related]
2. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
[TBL] [Abstract][Full Text] [Related]
3. Genomic features of rapid versus late relapse in triple negative breast cancer.
Zhang Y; Asad S; Weber Z; Tallman D; Nock W; Wyse M; Bey JF; Dean KL; Adams EJ; Stockard S; Singh J; Winer EP; Lin NU; Jiang YZ; Ma D; Wang P; Shi L; Huang W; Shao ZM; Cherian M; Lustberg MB; Ramaswamy B; Sardesai S; VanDeusen J; Williams N; Wesolowski R; Obeng-Gyasi S; Sizemore GM; Sizemore ST; Verschraegen C; Stover DG
BMC Cancer; 2021 May; 21(1):568. PubMed ID: 34006255
[TBL] [Abstract][Full Text] [Related]
4. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098
[TBL] [Abstract][Full Text] [Related]
5. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.
Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K
Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
BMC Cancer; 2021 Mar; 21(1):239. PubMed ID: 33676425
[TBL] [Abstract][Full Text] [Related]
7. Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer.
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Nagahashi M; Takabe K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933189
[TBL] [Abstract][Full Text] [Related]
8. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
9. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
BMC Cancer; 2021 Mar; 21(1):286. PubMed ID: 33726701
[TBL] [Abstract][Full Text] [Related]
11. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L
Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384
[TBL] [Abstract][Full Text] [Related]
12. Triple‑negative breast cancer therapy: Current and future perspectives (Review).
Won KA; Spruck C
Int J Oncol; 2020 Dec; 57(6):1245-1261. PubMed ID: 33174058
[TBL] [Abstract][Full Text] [Related]
13. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
14. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
15. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.
Jamiyan T; Kuroda H; Yamaguchi R; Nakazato Y; Noda S; Onozaki M; Abe A; Hayashi M
Breast Cancer; 2020 Sep; 27(5):880-892. PubMed ID: 32222891
[TBL] [Abstract][Full Text] [Related]
17. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
20. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]